March 30, 2020
Gibson Dunn’s lawyers regularly counsel clients on issues raised by the COVID-19 pandemic, and we are working with many of our clients on their response to COVID-19. The following is a round-up of today’s client alerts on this topic prepared by the Gibson Dunn team. Our lawyers are available to assist with any questions you may have regarding developments related to the outbreak. As always, for additional information, please feel free to contact the Gibson Dunn lawyer with whom you usually work, or any member of the firm’s Coronavirus (COVID-19) Response Team.
The COVID-19 outbreak has caused major disruptions in global economies, including in particular to life sciences companies that are conducting clinical trials and manufacturing and marketing pharmaceutical products. We provide ten actions that are among those that life sciences companies may wish to consider in light of current events.
Courts around the world have responded to the COVID-19 outbreak by delaying or suspending proceedings. While some courts have attempted to use technological solutions such as remote appearances by videoconference to mitigate delays, others have opted to postpone all proceedings deemed non essential. The status of matters pending before courts is changing on a daily basis, in most cases providing little clarity about when or how they will be addressed.